Dr. Mabel Mardones educates patients on breast cancer subtypes, as well as treatment options for those with ER-positive, HER2 ...

Vepdegestrant shows significant progression-free survival benefits over fulvestrant in advanced breast cancer, highlighting ...

Triple-negative breast cancer (TNBC) is one of the most aggressive and difficult-to-treat forms of breast cancer. Unlike ...

The Phase III DESTINY-Breast09 clinical trial has delivered groundbreaking results, demonstrating that ENHERTU® ...

Facing a diagnosis of hormone receptor-positive (HER2-positive) breast cancer can feel overwhelming. You're not alone in this journey, though. Understanding your treatment options and making informed ...

Vepdegestrant showed a benefit for patients with ER-positive, HER2-negative, ESR1-mutated breast cancer who had previously received endocrine-based therapy.

A newly developed molecular imaging technique can identify multiple subtypes of triple-negative breast cancer (TNBC), ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible ...

Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible ...

ACCURATE determination of HER-2 status in breast cancer is essential for guiding targeted therapy and improving clinical ...

Abstract:        Obesity, a growing global issue, has been closely associated with an increased risk of various cancers, especially breast cancer. El ...